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control and a positive inﬂuence on organ complications related
to hypertension may result in avoidance of huge costs due the
complications incidences.
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OBJECTIVE: To assess the cost-effectiveness of antihypertensive
treatment with nebivolol, atenolol or ACE inhibitor monother-
apy in 60-year and 70-year-old patients with moderate hyper-
tension in Germany. METHODS: Using a decision-analytic
Markov model, we determined incremental cost-effectiveness
ratios (ICER) of treatment with nebivolol, atenolol and ACE
inhibitor monotherapy from third party payers’ perspective over
a 5-year time horizon. Effects on diastolic blood pressure were
obtained from a pooled analysis of published randomized clini-
cal trials using response and compliance data. The 5-year
absolute risk for an initial coronary, cerebrovascular event or
cardiovascular death was computed using the gender speciﬁc
algorithm based on Framingham Heart Study data. Costs were
derived from published tariff lists. Direct medical costs per
patient included cost of drug treatment over the 5-year period
and cost of acute care for coronary and cerebrovascular events.
RESULTS: The comparison of nebivolol vs. ACE inhibitors
showed that 3.5 (60-year-old men) and 3.4 (70-year-old men) life
years more per 100 patients could be gained with nebivolol. With
higher incremental costs, ICER for nebivolol versus ACE
inhibitors was €2025 (60-year-old men) and €1824 (70-year-old
men). In comparison to atenolol, 6.3 (60-year-old men) and 5.7
(70-year-old men) life years more per 100 patients could be
gained. ICER for nebivolol versus atenolol was €4672 (60-year-
old men) and €4704 (70-year-old men) per life-year gained. For
women, the number of incremental life years gained was lower.
ICER for nebivolol versus ACE inhibitors were €2347 (60-year-
old women) and €1,904 (70-year-old women) and for nebivolol
versus atenolol €11,648 (60-year-old women) and €9060 (70-
year-old women) per life-year gained. CONCLUSION: Based on
our decision analysis, the use of nebivolol was more effective
than antihypertensive therapy with ACE inhibitors and atenolol.
Antihypertensive treatment with nebivolol is a cost-effective
treatment option from third party payer’s perspective in
Germany in the selected patient groups.
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OBJECTIVE: Indapamide is one of the most frequently pre-
scribed diuretics in Greece and the most expensive too. The
purpose of this study was to compare the cost-effectiveness of
indapamide with propranolol, amlodipine, enalapril and irbe-
sartan in the management of mild-to-moderate hypertension in
Greece. METHODS: A cost-effectiveness analysis was per-
formed from a third-party payer perspective, in 2004 Euros (€).
A decision analysis model was developed to compare the ﬁve
alternative interventions. Clinical inputs were derived from ran-
domized controlled trials and cost data from public sources. The
evaluation of the cost of managing hypertension includes the cost
of drug therapy, monitoring, treating side-effects, poor compli-
ance and switching. The DerSimonian and Laird method was
used for the meta-analysis. The time horizon was ﬁve years.
Future costs and health beneﬁts were discounted at 5%. Exten-
sive sensitivity analyses were performed. RESULTS: Old and new
drugs provided similar protection against total mortality and
major CVD events in mild-to-moderate uncomplicated hyper-
tension. The ﬁve-years total treatment cost was €550.99,
€582.04, €864.32, €622.30, and €1283.99 for indapamide, pro-
pranolol, amlodipine, enalapril and irbesartan respectively and
the estimated total cost to prevent one major cardiovascular
event was €16,239.77, €17,154.91, €25,474.88, €18,341.68 and
€37,844.09 respectively. Sensitivity analyses conﬁrmed the lower
cost-effectiveness ratio of indapamide in comparison with pro-
pranolol, amlodipine, enalapril or irbesartan. CONCLUSION:
In the management of mild-to-moderate hypertension in Greece,
indapamide is more cost-effective than propranolol, amlodipine,
enalapril or irbesartan. The results of this study support the last
recommendations of the Joint National Committee and the 
International Society of Hypertension. Indapamide should be
considered as the ﬁrst choice of antihypertensive treatment 
in uncomplicated hypertension.
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OBJECTIVES: To calculate the cost-effectiveness of daily treat-
ment of 160mg valsartan/25mg HCTZ for systemic arterial
hypertension (SAH) as compared with 16mg candesartan/
12.5mg HCTZ and with 80mg telmisartan/12.5mg HCTZ.
METHODS: The information used in this model originates from
a study comparing therapeutic effectiveness of valsartan/HCTZ
in combination versus combinations of candarstan/HCTZ and
of telmisartan/HCTZ for the treatment of SAH. Patients received
16mg candesartan/12.5mg HCTZ or 80mg telmisartan/12.5mg
HCTZ daily for 4 weeks. The Mean Sitting Diastolic Blood
Presure (MSDBP) was measured at the beginning and at the end
of the 4-weeks treatment. Those patients who were not con-
trolled using either of these regimens (MSDBP° 90mmHg)
were given daily doses of 160mg valsartan/25mg HCTZ for a
further 4 weeks. RESULTS: Patients who received 16mg can-
desartan/12.5mg HCTZ or 80mg telmisartan/12.5mg HCTZ
showed a 28% success rate in achieving a MSDBP <90mm Hg.
Patients who received 160mg valsartan/25mg HCTZ demon-
strated a 74% success rate for the same parameter. Furthermore,
the reduction in MSDBP in those patients who received 160mg
valsartan/25mg HCTZ was 10.3mm Hg greater than that
obtained in the ﬁrst phase of the study (p < 0.0001). The only
important difference in the use of medical resources related to
these therapies was the cost of the medicines involved. The
monthly anti-hypertensive treatment cost for the 160mg valsar-
tan/25mg HCTZ combination was the lowest of the three com-
binations at $295.71 Mexican pesos (US$26.88) as compared
with $354.54 Mexican pesos (US$32.23) for the 16mg can-
desartan/12.5mg HCTZ combination and $428.51 Mexican
pesos (US$38.95) for 80mg telmisartan/12.5mg HCTZ. CON-
CLUSIONS: The combination of 160mg valsartan/25mg HCTZ
is more effective and less expensive than either 16mg candesar-
tan/12.5mg HCTZ or 80mg telmisartan/12.5mg HCTZ.
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According to these ﬁndings, treatment with 160mg valsartan/
25mg HCTZ totally dominates and it should be preferable. Sen-
sitivity analysis conﬁrmed the results from this base case.
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OBJECTIVES: Hypertension is a highly prevalent risk factor for
cardiovascular disease (CVD), which affects approximately 50
million Americans. The outcome data from several clinical trials
and meta-analyses prove that new and old classes of antihyper-
tensive drugs provide similar reductions of cardiovascular mor-
bidity and mortality. The purpose of this study was to compare
the costs associated with the prescription of ﬁrst-line anti-
hypertensive agents in United States (US). METHODS: A cost-
minimization analysis was performed. A decision analysis model
was developed to compare the ﬁve alternative interventions:
chlorthalidone, propranolol, amlodipine, enalapril and losartan.
Clinical inputs were derived from randomized controlled trials
and cost data from 2004 Red Book and Centers for Medicare &
Medicaid Services. The evaluation of the cost of managing mild-
to-moderate hypertension includes the cost of drug therapy,
monitoring, treating side-effects, poor compliance and switching.
All costs were calculated from a health system’s perspective, in
2004 $US. Future costs and clinical beneﬁts were discounted at
5%. The time horizon was 5 years. RESULTS: The total cost to
achieve and maintain hypertension control in US setting was
$2194.42, $3181.79, $3566.36, $2885.69 and $3747.57 for
chlorthalidone, propranolol, amlodipine, enalapril and losartan
respectively. The drug acquisition cost was 27.54%, 51.28%,
58.18%, 47.83%, and 61.55% respectively. Sensitivity analysis
tested the effect of modifying the prices of the antihypertensive
agents and laboratory monitoring, the doses of the alternative
drugs and the compliance rate on the economic endpoints and
conﬁrmed the superiority of chlorthalidone. CONCLUSIONS:
In patients with mild-to-moderate hypertension in US, treatment
costs to prevent CVD are much lower with chlorthalidone than
with the other ﬁrst-line antihypertensive agents.
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Despite therapeutic advances, High Blood Pressure (HBP)
remains a health issue in Western countries. Few programs have
sought to improve physician-patient relationship and the effect
of educating HBP patients. CV@Goal is a French educational
programme (2002 to 2003) aimed at training physicians to
educate HBP patients. OBJECTIVES: Assessing the impact of
CV@Goal on HBP patients and physicians. METHODS: A 6-
month before-after comparison of physician and HBP patient
populations. Four HBP patients per GPs were included. GPs were
trained to educate HBP patients and included four new HBP
patients. RESULTS: In total, 1208 HBP patients and 308 physi-
cians completed the “before” questionnaire, and after training
512 new patients and 169 physicians completed the “after” ques-
tionnaire. According to GPs, there were in both phases “impor-
tant” or “insurmountable difﬁculties” concerning patient seden-
tary lifestyle (40%), diet compliance (60%) and alcohol (75%).
The proportion of GPs who considered patient knowledge to be
“good” or “very good” increased for: general issues (22% to
38%), the disease natural history (8% to 14%), risks (29% to
49%), complication prevention (13% to 24.5%) and alarm
symptoms (21% to 35%); the proportion also increased for
patient awareness of the importance of smoking cessation (69%
to 77%) and special dieting (52% to 67%). Changes in patients’
blood pressure were not signiﬁcant. Most patients believed
smoking, diabetes, alcohol, hypercholesterolemia, treatment
compliance, obesity, age, heredity and diet could alter blood
pressure; knew HBP could relate to heart, brain, arteries, eyes,
kidneys complications; that smoking cessation, weight loss,
physical exercise and salt reduction could improve HBP. After
CV@Goal, improvements were observed in patient knowledge
about the importance of weight loss, physical exercise and salt
consumption. Nevertheless, most patients declare they have not
changed lifestyle since the HBP diagnosis. CONCLUSION:
CV@Goal had an impact on patient knowledge about HBP, but
not on lifestyle and BP.
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OBJECTIVES: Hypertensive patients with cardiovascular (CV)
disease or diabetes are at a particularly high CV risk. LDL-
cholesterol (cLDL) levels are an important CV risk factor and
total cholesterol/cHDL (TC/HDL) ratio is also related to car-
diovascular risk. Although HDL-cholesterol (cHDL) is a protec-
tive factor, available therapeutic strategies are not effective
enough. The objective of this study is to compare cLDL, cHDL
and TC/HDL between two groups: patients with previous CV
disease/diabetes and those without it in a hypertensive popula-
tion from a programme for CV risk control. METHODS: A total
of 5094 subjects from primary care centres in Spain were retro-
spectively studied. Levels of cLDL, cHDL and TC/HDL were
compared for the above mentioned groups by Student t test for
independent samples. RESULTS: There were 41.4% men. Mean
age 66.3 years. Average TC levels were: 214.4mg/dL; cLDL:
141.9mg/dL; cHDL: 45.5mg/dL and TC/HDL: 4.98. Levels of
cLDL were signiﬁcantly lower for those with CV disease/dia-
betes: 148.6mg/dL (SD 32.8) vs. 132.3mg/dL (SD 35); p <
0.0001. Similarly, Levels of cHDL were signiﬁcantly lower 
for those with CV disease/diabetes: 47.1mg/dL (SD 12.5) vs.
43.1mg/dL (SD 11.4): p < 0.0001. There were no signiﬁcant dif-
ferences of CT/HDL ratio between groups. CONCLUSIONS: In
a population of treated hypertensives, cLDL levels are lower for
those with previous CV disease/diabetes, which is appropriate
taking into account their higher cardiovascular risk. On the con-
trary cHDL levels are lower in the group at highest risk. There
is a wide room for improvement of cardiovascular risk in hyper-
tensive patients with previous CV disease or diabetes, by increas-
ing HDL.
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